Colorectal Cancer

Latest News

November 1st 2005

Novel Vaccines for the Treatment of Gastrointestinal Cancers

Continuing advances in immunology and molecular biology duringthe past several decades have provided optimism that immunomodulatorystrategies may be clinically useful in patients with cancer.Key advances have included: (1) recognition of the critical role of theantigen-presenting cell and greatly improved understanding of antigenprocessing and presentation, including the molecular interactionsbetween HLA molecules and antigenic epitopes on the antigen-processingcell and the receptors on T cells, and (2) the roles ofcostimulatory molecules such as B7.1, ICAM-1, and LFA-3 in the inductionand maintenance of an immune response. In addition, newtechniques have allowed us to identify immunogenic antigenic determinants,alter their binding affinities, and evaluate the overall successof the intervention through both in vivo and in vitro assays.Carcinoembryonic antigen (CEA) is overexpressed in a large numberof gastrointestinal, lung, and breast cancers. Clinical trials have establishedtreatment protocols using viral vectors to immunize patients toCEA without producing deleterious autoimmune phenomena. By combiningvarious vectors to include MUC-1 and/or CEA plus costimulatorymolecules in a prime-and-boost regimen, we are beginning to see signsthat this intervention can not only produce changes in immune functionbut also potentially improve clinical outcomes. Phase III studies totest these hypotheses are under way.

October 1st 2005

SLNM May Reduce Colon Ca Recurrences by Upstaging Patients Who May Then Receive Adjuvant Chemotherapy

October 1st 2005

FOLFOX4 + Avastin Ups Survival in Colorectal Ca

August 1st 2005

Metastatic Colorectal Cancer: Is There One Standard Approach?

By Leonard B. Saltz, MD

August 1st 2005

Reduced-Dose Capecitabine May Be Reasonable Alternative to Combination Chemotherapy

CME Content

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Tennessee

Sapna Patel, MD; Jack W. Erter III, MD, MMHC

Virtual Event

Examining the Role of ctDNA in the Management of Breast Cancer: Latest Evidence and Future Directions

October 15, 2025

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Arizona

Yana G. Najjar, MD; Rakesh Bagai, MD

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Tumor Board: Advances in Managing EGFR-Mutant NSCLC—Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

In-Person + Virtual Event

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

October 26, 2025

Video

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

Video

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Iowa

Sapna Patel, MD; Rakesh Bagai, MD

In-Person Event

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Multimedia

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD

Video

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Richard S. Finn, MD; Anthony B. El-Khoueiry, MD; Pierre Gholam, MD; Lipika Goyal, MD

Multimedia

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Kathleen N. Moore, MD, MS, FASCO; Susana Banerjee, MBBS, MA, FRCP, PhD; David M. O’Malley, MD; Ritu Salani, MD, MBA

Video

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Mark G. Kris, MD; Justin Gainor, MD; Isabel Preeshagul, DO, MBS; Helena A. Yu, MD

Multimedia

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD

Multimedia

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA

Multimedia

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Kathleen N. Moore, MD, MS, FASCO; Prof Susana Banerjee, MBBS, MA, FRCP, PhD

Multimedia

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS, FASCO; David M. O’Malley, MD

In-Person + Virtual Event

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

December 5, 2025

In-Person + Virtual Event

Breast Cancer Symposia in San Antonio

December 8-11, 2025

Multimedia

Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?

Jae H. Park, MD

Multimedia

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Tiffany A. Traina, MD, FASCO; Demetria Smith-Graziani, MD, MPH

Video

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Mark Agulnik, MD; Shaina A. Rozell, MD, MPH

Video

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Lee M. Zuckerman, MD

Multimedia

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Daniel Lefler, MD; Shaina A. Rozell, MD, MPH; Lee M. Zuckerman, MD

Case-based Simulation

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Mark Agulnik, MD; Daniel Lefler, MD

In-Person Event

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

January 22, 2026

In-Person Event

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Video

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Naval G. Daver, MD; Jessica Altman, MD; Amir T. Fathi, MD; Gail J. Roboz, MD; Joshua Zeidner, MD

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Video

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

In-Person Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Benefit of FOLFOX4 Confirmed at 4-Year Follow-up of MOSAIC Trial

August 1st 2005

PARIS, FRANCE-Analysisof disease-free survival data at 4 yearsinto the MOSAIC trial “amplifies thebenefit of FOLFOX4 obtained at 3

XELOX Is Active in Elderly Patients With Metastatic Colorectal Cancer

August 1st 2005

NAPLES, ITALY-As firstlinetherapy in elderly patients withmetastatic colorectal cancer, XELOX(capecitabine [Xeloda] and oxaliplatin(Eloxatin]) achieved an objectivetumor response rate of 41% (abstract

XELOX Effective First-Line Treatment for Elderly Patients With Metastatic Colorectal Cancer

August 1st 2005

ORLANDO-XELOX (capecitabine[Xeloda] and oxaliplatin [Eloxatin])is effective and well tolerated asfirst-line treatment for elderly patients

Oral XELOX Regimen Comparable to FOX in Advanced Colorectal Ca, Preliminary Data Show

August 1st 2005

BOLOGNA, ITALY-Preliminaryresults of a small phase II advancedcolorectal cancer trial comparinga protracted fluorouracil

Oral Capecitabine May Simplify Chemoradiotherapy for Rectal Cancer

August 1st 2005

HOUSTON-Concomitantboost radiotherapy plus capecitabine(Xeloda) produces pathologic responserates comparable to those of

XELOX Shows Favorable Safety Profile vs FOLFOX6 in Metastatic Colorectal Cancer

August 1st 2005

VILLEJUIF, FRANCE-In thefirst randomized comparison of aschedule of FOLFOX6 (fluorouracil[5-FU], leucovorin, oxaliplatin [Eloxatin])vs standard XELOX (capecitab

Bevacizumab Increases Efficacy of Oxaliplatin- Based Chemotherapy for Metastatic CRC

August 1st 2005

NEW YORK-Adding bevacizumab(Avastin) to oxaliplatin [Eloxatin]/fluorouracil or to oxaliplatin/capecitabine (Xeloda) improves re

XELOX With Bevacizumab Is Highly Active in Metastatic Colorectal Ca, Preliminary Data Show

August 1st 2005

DURHAM, North Carolina-The addition of bevacizumab(Avastin) to XELOX (capecitabine[Xeloda] and oxaliplatin [Eloxatin])results in a new, highly active regimen

CapeOx, 5-FU-Oxaliplatin Similar in Advanced CRC

August 1st 2005

MADRID, SPAIN-Preliminaryresults of a phase III trial comparingcapecitabine (Xeloda) and oxaliplatin(Eloxatin)(CapeOx) with

UFT/Leucovorin: An ‘Excellent Alternative’ to 5-FU/Leucovorin in Colorectal Cancer

August 1st 2005

NEW YORK-The combinationof UFT (an oral fluoropyrimidineconsisting of tegafur plus uracil) andleucovorin “is tolerable and efficacious”and “an excellent alternative to

XELOX-RT Is Practical Regimen for Borderline Resectable Rectal Cancer

August 1st 2005

ORLANDO-Neoadjuvantcapecitabine (Xeloda), oxaliplatin(Eloxatin), and preoperative pelvicradiotherapy (XELOX-RT) is a welltoleratedregimen in patients with locallyadvanced rectal cancer and pro

Sequential Use of XELOX and XELIRI May Allow Greater Use of Oxaliplatin in Patients With Metastatic Colorectal Cancer

August 1st 2005

GUADALAJARA, SPAIN-Sequentialcycling of XELOX (capecitabine[Xeloda]/oxaliplatin [Eloxatin])and XELIRI (capecitabine/irinotecan

Good Safety Profile Reported for Biweekly Schedule of Capecitabine and Irinotecan

August 1st 2005

MADRID, SPAIN-Capecitabine(Xeloda) plus irinotecan (Camptosar),in a biweekly schedule as firstlinetreatment of locally advanced ormetastatic colorectal cancer, is an activeschedule with a manageable tox

CAPOX Demonstrates Equivalent Efficacy and Toxicity to FUFOX in First-Line Setting for Patients With Advanced Colorectal Cancer

August 1st 2005

BREMEN, GERMANY-CAPOXand FUFOX have comparabletoxicity profiles and efficacy in thefirst-line treatment of metastatic col

FOLFIRI Preferred Over IROX for First-Line Treatment of Metastatic Colorectal Cancer

August 1st 2005

MUNICH, GERMANY-Irinotecan(Camptosar) plus fluorouracil(5-FU)/folinic acid (FOLFIRI) issignificantly better at controlling

Disappointing Early Results With PTK/ZK in Patients With Advanced Colorectal Cancer

August 1st 2005

ORLANDO-Preliminary datafrom a randomized, double-blind, placebo-controlled phase III trial showedthat the angiogenesis inhibitor PTK/

Bevacizumab May Enhance Cetuximab/Irinotecan Efficacy in Refractory Colorectal Cancer

August 1st 2005

NEW YORK-“Bevacizumab(Avastin) appears to add to theefficacy of cetuximab (Erbitux) and

Promising Efficacy for Preoperative Chemoradiotherapy With Capecitabine/ Irinotecan in Locally Advanced Rectal Cancer

August 1st 2005

MANNHEIM, GERMANY-Complete or nearly complete responsesoccurred in 41% of patients in aphase II trial of capecitabine (Xeloda)

Oral Capecitabine Is Attractive Alternative to Continuous- Infusion Regimens

August 1st 2005

BIRMINGHAM, ALABAMA-“Capecitabine can replace continuousinfusion in regimens to treat colorectalcancer,” Scott Cole, MD, and colleaguesat the University of Alabama

Adding Bevacizumab to FOLFOX4 Improves Survival in Metastatic Colorectal Cancer

August 1st 2005

ORLANDO-“Adding highdosebevacizumab (Avastin) to FOLFOX4improves overall survival, diseaseprogression-free survival (PFS),

Adjuvant Capecitabine Bests Bolus 5-FU/LV in Patients With Dukes’ C Colon Cancer

August 1st 2005

ORLANDO-At a median follow-up of 51 months, data reported atASCO from the X-ACT phase III trial

XELOX Compares Favorably With FOLFOX4 in Adjuvant Therapy for Colorectal Cancer

August 1st 2005

ORLANDO-In first-line metastaticcolorectal cancer, capecitabine(Xeloda) is better tolerated than fluorouracil/leucovorin (5-FU/LV), and

5-FU/Leucovorin Plus Oxaliplatin Significantly Improves Disease- Free Survival in Colorectal Ca Pts

August 1st 2005

ORLANDO-The additionof oxaliplatin (Eloxatin) to weekly bolusfluorouracil/leucovorin (5-FU/LV)

Panitumumab Effective in Heavily Pretreated Metastatic CRC

August 1st 2005

ORLANDO-Panitumumab,which binds to the epidermalgrowth factor receptor (EGFR), “demonstratedencouraging antitumor ac

Commentary (Grem)-Metastatic Colorectal Cancer: Is There One Standard Approach?

ByJean L. Grem, MD, FACP

August 1st 2005

In this issue, Dr. Saltz articulateshis opinion on a variety of questionsconcerning therapy for patientswith metastatic colorectal cancer.My commentary will reflect myopinions concerning these questions.